Peploc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peploc

What is Peploc? An Overview

Property Description
Active Ingredient Ranitidine Hydrochloride
Pharmacological Class Histamine H₂-receptor antagonist (H₂-blocker)
Common Use Relief of symptoms associated with excessive stomach acid
Origin Synthetic small molecule
Forms Tablet, capsule, oral solution, injection

Peploc: Classification and Active Ingredient

Peploc is a pharmaceutical preparation whose primary role is to reduce the production of stomach acid, classified scientifically as a Histamine H₂-receptor antagonist (H₂-blocker). The compound responsible for this effect is the active ingredient, Ranitidine Hydrochloride. This drug is a synthetic small molecule that acts as a single agent, which means its composition is chemically defined by this one active substance. The H₂-antagonist class functions by selectively interrupting specific chemical signals within the body that stimulate the gastric cells to produce acid. H₂-receptor antagonists provide modulation of acid secretion, assisting in the management of how much acid the stomach produces.


Available Forms, Purpose, and Differentiation

Peploc is manufactured in a variety of physical presentations, facilitating different routes of administration to suit patient needs. Common dosage form(s) include the tablet and capsule for oral intake, as well as an oral solution and a sterile solution designated for injection (parenteral administration). This availability across forms supports its general purpose: to mitigate irritation and discomfort caused by hyperacidity, or the condition of excessive stomach acid. The essential goal of using a formulation containing Ranitidine is to provide relief by addressing the root cause of acid-related symptoms, such as the burning sensation of heartburn. The medication is used to reduce gastric acid volume.


The Core Function: Sustained Reduction of Stomach Acid Secretion

The fundamental function of Peploc is to act as a potent antisecretory agent, achieving a sustained reduction in gastric acid secretion. It operates by reversibly binding to specific receptors on the stomach's acid-producing cells, effectively blocking one of the primary triggers for acid release. This results in a measurable decrease in the volume and corrosiveness of the stomach's digestive juices. The benefit of this targeted action is a continuous modulation of the acidic environment in the upper gastrointestinal tract, promoting symptomatic relief.

Regulatory References

  1. Ranitidine: LiverTox - NCBI Bookshelf - NIH
  2. RANITIDINE tablet - DailyMed

What side effects are possible with Peploc?

Possible Side Effects and Safety Information

The official safety profile for Peploc (ranitidine) is structured by regulatory authorities to classify potential adverse reactions based on their frequency and the body system affected.

Adverse Reaction Classifications

Side effects are formally grouped according to their documented likelihood of occurrence, consistent with regulatory guidelines.

Classification Examples of Officially Documented Effects
Common Headache.
Uncommon Abdominal pain or discomfort, constipation, and nausea, which may improve with continued treatment.
Rare Transient changes in liver function tests (elevated aminotransferase levels) and hypersensitivity reactions (e.g., urticaria, bronchospasm).
Very Rare Reversible mental confusion, dizziness, cardiac effects such as bradycardia or tachycardia, and blood count changes.

Serious Adverse Reactions and Safety Constraints

Although rare, the regulatory labeling documents serious adverse reactions, including hepatitis (with or without jaundice), acute pancreatitis, and severe blood disorders (e.g., agranulocytosis, pancytopenia). Cardiac events such as asystole are also noted in the safety documentation.

Specific safety considerations exist for certain populations. Safety information notes that the risk of reversible mental confusion is increased in older adults and those with existing renal or hepatic impairment. Furthermore, the medicine is restricted for use in patients with a history of acute porphyria.

Crucially, regulatory authorities have highlighted the potential formation of the impurity N-nitrosodimethylamine (NDMA), a probable human carcinogen, leading to the withdrawal of many ranitidine products globally. It is also an official constraint that symptomatic relief from this medicine does not preclude the presence of gastric malignancy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Peploc (Ranitidine Hydrochloride) specifies the formal documentation regarding overdose manifestations and required emergency actions that must be taken.

Category Documented Manifestations / Actions
Documented Clinical Signs Overdose may result in an exaggeration of known side effects, which are generally expected to be transient. Specific presentations documented in regulatory labeling include fainting, tachycardia (abnormally rapid heart rate), and gait disturbances (difficulty walking).
Severe Outcomes Severe central nervous system (CNS) toxicity, including the manifestation of seizures, and adverse cardiovascular effects such as bradycardia and arrhythmias, have been associated with massive exposure.
Emergency Response Individuals who suspect an overdose or have taken a dose higher than prescribed must seek immediate medical attention. Management is primarily symptomatic and supportive, and regulatory labeling states that no specific antidote is known.
Special Considerations Overdose severity is noted to be increased in patients with impaired renal function due to reduced drug clearance. Hospital monitoring is required until the patient's condition stabilizes, and procedural steps like gastric lavage or even hemodialysis may be utilized in severe cases.

This profile is established by official regulatory authorities to communicate the expected clinical presentations and define the mandatory help-seeking actions in an overdose scenario, emphasizing the need for professional medical intervention.

Therapeutic Uses of Peploc

Main Uses and Benefits of Peploc

Peploc, containing the active ingredient famotidine, belongs to a class of medications known as histamine-2 (H2) receptor antagonists. It is primarily used to manage conditions related to excess gastric acid production in the stomach and esophagus.

Primary Indications

  • Treatment of Gastric and Duodenal Ulcers: Peploc is used to treat active ulcers in the stomach or the upper part of the small intestine. By reducing acid production, it allows the lining of the digestive tract to heal.
  • Gastroesophageal Reflux Disease (GERD): The medication is utilized to manage symptoms of acid reflux, where stomach acid flows back into the esophagus, causing discomfort or inflammation.
  • Prevention of Ulcer Recurrence: It may be used as a maintenance therapy to prevent duodenal ulcers from returning after they have healed.
  • Hypersecretory Conditions: Peploc is indicated for rare conditions where the stomach produces excessive amounts of acid, such as Zollinger-Ellison syndrome.

Therapeutic Benefits

  • Symptom Relief: Peploc helps alleviate the burning sensation in the chest (heartburn) and acid indigestion associated with acid reflux and sour stomach.
  • Mucosal Healing: By decreasing the acidity of gastric juices, the medication provides an environment conducive to the repair of the esophageal and gastrointestinal lining.
  • Acid Regulation: Unlike antacids which neutralize existing acid, Peploc works by inhibiting the receptors responsible for acid secretion, providing a more sustained reduction in stomach acidity.

Regulatory References

  1. NIH DailyMed listing for ranitidine

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population or Condition
Contraindicated Patients with a known hypersensitivity to ranitidine or any component of the formulation.
Contraindicated Patients with a history of acute porphyria.
Established Use Adults and pediatric patients aged 1 month to 16 years for approved indications.
Conditional Use Patients with impaired renal function (kidney disease).
Caution Required Severely ill geriatric patients due to increased risk of reversible confusion.
Pregnancy Status Category B. Acceptable only if clearly needed.
Lactation Status Caution should be observed, as the drug is excreted into human milk.

Official Eligibility Constraints

Official regulatory documents define strict boundaries for Peploc use. The medicine is contraindicated and must be avoided by anyone with a known ranitidine allergy or a history of acute porphyria. While use is established in adults and most children, specific physiological constraints apply: patients with impaired renal function require that use be conditional on a dosage adjustment, and those with suspected gastric malignancy must have the condition excluded before continuing treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Peploc (Ranitidine) based on two primary mechanisms: altering gastric acidity and competing for elimination pathways.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Outcome Description
pH-Mediated Absorption Medicines requiring an acidic environment for absorption (e.g., Ketoconazole, Atazanavir, Dasatinib) Co-administration leads to reduced absorption and lower plasma concentrations of the acid-soluble medicine.
Renal Transporter Competition Procainamide Ranitidine reduces the renal clearance of Procainamide, resulting in increased plasma exposure of Procainamide.

Interaction-Related Restrictions and Requirements

Peploc has been documented to have minimal or no clinically significant inhibitory effect on the primary hepatic CYP P450 enzyme system at therapeutic doses.

One co-administered substance requires mandatory timing separation: high-dose Sucralfate (e.g., 2 grams) may reduce the absorption of Peploc itself. To prevent this effect, high-dose Sucralfate must be administered at least two hours apart from Peploc. No specific drug combination is listed as formally contraindicated due to interaction risk alone in the regulatory summaries examined.

Mechanism of Action

Competitive Blockade of Gastric Histamine Receptors

Peploc operates as a competitive antagonist targeting the Histamine H₂-receptors (H₂R) found on the stomach's acid-producing parietal cells. By binding reversibly to these receptors, the drug directly blocks the primary chemical instruction that stimulates acid secretion, initiating the resultant molecular cascade.


Modulation of Intracellular Signaling Cascades

The H₂R blockade leads to the interruption of the intracellular cAMP pathway, the key second messenger system within the cell. This signal disruption functionally limits the capacity of the cell to activate the Proton Pump (H^+/K^+-ATPase), which is the final executioner of acid release.


Suppression of Gastric Fluid Output

This indirect inhibition of the Proton Pump results in the core physiological change: a measurable, sustained reduction in both basal and stimulated gastric acid output. This mechanism leads to a decrease in the overall hydrogen ion concentration and volume of the gastric fluid, thereby altering the characteristics of the gastric fluid.

Dosage and Administration Information

How to Use Peploc: Official Administration Guidelines

Peploc (Ranitidine) is administered according to established routes, doses, and schedules defined in prescribing information. The medication is available for oral administration (tablets, capsules, and solution) and parenteral administration (Intramuscular or Intravenous injection).

Standard Dosing Regimens (Adults)

The dose frequency and strength vary based on the specific regimen:

  • Active Treatment: The typical oral adult dose is 150 mg twice daily or an alternative of 300 mg once daily at bedtime.
  • Maintenance: A reduced oral dose of 150 mg once daily is utilized, usually taken at bedtime.
  • Intravenous/Intramuscular: The standard parenteral dose is 50 mg administered every 6 to 8 hours, with a maximum daily dose of 400 mg for most regimens.

Special Instructions and Conditions

Condition / Requirement Official Guideline
Timing Relative to Meals Oral doses may be taken without regard to meals. Once-daily doses are scheduled at bedtime or after the evening meal.
Preparation Effervescent tablets must be fully dissolved in a glass of water before consuming. Intravenous bolus injection should be administered slowly (over a minimum of 2 minutes).
Renal Impairment For patients with severe renal function impairment (creatinine clearance < 50 mL/min), the oral dose is reduced to 150 mg every 24 hours.
Treatment Duration Short-term active treatment typically lasts 4 to 8 weeks. Maintenance therapy, where indicated, can be continued for up to 1 year.

Pediatric dosing (1 month to 16 years) is weight-based (e.g., mg/kg) and administered in divided doses, with specified maximum daily limits.

Recent Clinical Evidence

Research evidence / Overview of studies for Peploc

Evidence for Use in Gastroesophageal Reflux Disease (GERD) and Heartburn

Research examined the patterns observed in symptoms associated with acid reflux. Peploc was evaluated in short-term Randomized Controlled Trials (RCTs) involving adult populations with conditions characterized by fluctuating or episodic manifestations like heartburn, sour stomach, and mild erosive esophagitis. Studies explored outcomes related to physical discomfort and changes in acid reflux symptoms, such as the intensity of acid-related perceived discomfort and changes in the measured use of antacid medications. Findings describe patterns observed in the studies related to symptom changes measured during the study period.

Evidence for Healing Duodenal and Gastric Ulcers

Peploc was evaluated in studies involving conditions associated with acute or disruptive episodes, specifically active duodenal and benign gastric ulcers. Research examined outcomes linked to inflammatory or irritative states, with controlled RCTs monitoring measurements of ulcer healing rates and monitoring of recurrence patterns. Studies monitored endoscopically confirmed changes in ulcer status over a fixed time interval, typically four to eight weeks. Research highlights changes measured during the study period, including patterns observed in ulcer healing rates.

What is Still Uncertain About the Research for Peploc

Follow-up durations were limited for many chronic conditions, meaning long-term effects are not fully established. Additionally, sample sizes were modest in the specialized studies, such as those related to high acid production conditions. Findings showed variability across some older studies, and certainty remains low regarding the generalizability of results beyond the specific populations studied. Comparative evidence against alternative treatment classes is limited. Data for certain groups, including pediatric patients, remain insufficient, and research describes limited insight into observed dosage patterns or long-term effects in these younger populations.

Key Studies & References

  1. Ranitidine Oral Solution, Tablet, and Injectable Label (Original Indications and Use)
  2. National Institute for Health and Care Excellence (NICE) Guideline: Gastro-oesophageal reflux disease and dyspepsia in adults

Frequently Asked Questions (FAQ)

Common questions about Peploc (FAQ)

Q: How quickly should I feel better after taking Peploc?

Studies and official information indicate that symptomatic relief for conditions like GERD and heartburn commonly occurs within 24 hours after starting a standard treatment dose. This action generally begins to reduce acid production shortly after administration. The full healing of conditions like ulcers will, however, require consistent use over a longer period as directed by the prescribing information.


Q: How long does the effect of one dose of Peploc last?

According to official product information, a single oral dose is typically effective at reducing stomach acid secretion for up to 12 hours. This sustained action supports the recommended interval between doses as authorized by regulatory bodies.


Q: I'm taking an antibiotic; is it okay to take Peploc at the same time?

Official drug information indicates that Peploc may affect the absorption of certain medicines, such as antifungals like Ketoconazole, that require an acidic stomach environment to be properly absorbed into the body. This interaction can lower the concentration of the co-administered medicine. The effects vary for other classes of antibiotics, and patients are typically advised to follow any specific timing instructions provided by a healthcare professional.


Q: Can women who are planning to become pregnant use Peploc?

Peploc is classified as Pregnancy Category B by regulatory bodies, but official labeling does not contain specific guidance regarding use while actively planning pregnancy. Official information states that risk cannot be ruled out. As with any medication, use during this period should be discussed with a healthcare provider.


Q: Why is consistent use of Peploc important for healing?

Clinical trials that demonstrated Peploc's effectiveness in healing conditions like duodenal and gastric ulcers required patients to take the medicine consistently over periods of 4 to 8 weeks. This consistent use is considered necessary to maintain a low-acid environment that supports the body's natural healing process.


Q: Does Peploc cause extreme fatigue or drowsiness?

Official adverse reaction reports indicate that somnolence (drowsiness) and malaise (a general feeling of discomfort or unease) are reported rarely as central nervous system side effects. While they are noted in the safety profile, they are not expected to be common.


Q: Can Peploc be taken with my daily multivitamin?

Since Peploc is an acid reducer, it alters the stomach environment, which may reduce the absorption of certain substances that need stomach acid to dissolve properly. Official labeling does not specifically name multivitamin ingredients, but the drug's effect on acid levels should be considered for any substance that requires stomach acid for absorption.


Q: Are there any long-term effects of using Peploc?

Official prescribing information notes that clinical trials for long-term use have typically not extended beyond 1 year for maintenance therapy. Therefore, long-term effects, particularly beyond a year, are not as fully established or studied as short-term effects, according to regulatory reviews.


Q: Does Peploc affect my blood pressure or heart rate?

Official safety data reports that rare cardiovascular adverse reactions have been noted. These include arrhythmias such as both tachycardia (a fast heart rate) and bradycardia (a slow heart rate).


Q: Can taking Peploc cause changes in mood or anxiety?

Official documentation reports rare cases of Central Nervous System effects, including depression and agitation. These effects are noted predominantly in severely ill elderly patients, suggesting they are uncommon.


Q: Is Peploc more effective if taken before or after a meal?

According to official regulatory instructions, oral doses of the medicine may be taken without regard to meals. Official guidance for certain uses, such as heartburn prevention, may suggest taking the medication shortly before consuming known triggers.


Q: Can Peploc cause hair thinning or loss?

Official adverse reaction reports indicate that alopecia (hair loss or thinning) has been reported in rare cases. This effect is noted in the regulatory safety profile but is considered a rare occurrence.


Q: Are there any foods or drinks I should avoid while on Peploc?

The oral solution form of the medication contains 7.5% w/v alcohol. Additionally, over-the-counter labels advise that for heartburn prevention, the medicine should be taken 30 to 60 minutes before eating or drinking certain foods and beverages that are known to cause heartburn. Patients using the solution should be aware of this factor.


Q: What are the common signs that Peploc is working?

The drug is intended to provide symptomatic relief from acid-related discomfort, such as heartburn, sour stomach, and pain. In clinical studies, success was measured by a reduction in acid-related discomfort and a change in the use of antacid medications. For ulcers, the goal is successful healing over time.


Q: What if Peploc doesn't seem to be working for my symptoms?

Official labeling for the over-the-counter form advises that patients should discontinue use and seek professional medical advice if heartburn continues, worsens, or lasts longer than two weeks. Furthermore, official prescribing information notes that even if symptoms improve, this medicine does not rule out the presence of a more serious condition, such as gastric malignancy.


Q: Can I drink alcohol in moderation while taking Peploc?

While warnings about interactions with ingested alcohol are not universally listed, patients using the oral solution should be aware that this specific formulation contains 7.5% w/v alcohol.


Q: Is it okay to crush or split Peploc tablets?

Regulatory instructions for the effervescent tablets state that they must be fully dissolved in a glass of water before consuming. Official administration instructions do not provide guidance or authorization for crushing or splitting standard tablets.


Q: Does Peploc cause diarrhea or constipation?

According to official safety data, both constipation and diarrhea are listed among the possible gastrointestinal adverse reactions. Constipation is specifically categorized as an uncommon side effect.


Q: Why is Peploc sometimes used for people with ulcers?

Peploc is authorized for use in the treatment of active duodenal and benign gastric ulcers. This is based on clinical trials that evaluated its ability to promote the healing of ulcers and reduce the patterns of their recurrence. The acid reduction is a key action for addressing this condition.

How should Peploc be stored and disposed of?

How to Store and Dispose of Peploc

Peploc tablets must be stored according to regulatory requirements to ensure product integrity, particularly related to temperature and environmental protection.

Storage Requirements

Condition Requirement
Temperature Store at or below 25°C or 30°C, as specified on the label.
Protection Protect from excess moisture and light.
Container Keep in the original container, tightly closed, with the desiccant inside.
Child Safety Must be kept out of the sight and reach of children.

Tablets in an opened bottle must be discarded after 90 days. The medication must not be used after the expiration date printed on the label.

Disposal

Unused or expired Peploc must be disposed of according to official regulatory guidance. The medicine should not be disposed of in drains, sewerage systems, or by flushing. Unused product should be returned to a pharmacist for appropriate pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peploc found in:

A-Z Index: